Tags

Type your tag names separated by a space and hit enter

Pharmacological Treatments for Patients with Treatment-Resistant Depression.
Pharmaceuticals (Basel). 2020 Jun 04; 13(6)P

Abstract

Over a third of patients with major depressive disorder (MDD) do not have an adequate response to first-line antidepressant treatments, i.e., they have treatment-resistant depression (TRD). These patients tend to have a more severe course of illness and are at an increased risk of suicide. Next step treatment options for patients with TRD, include switching to a different antidepressant, combining more than one antidepressant, or augmenting an antidepressant with another (non-antidepressant) medication. It is unclear which of these treatment approaches should be applied to a given patient, and in what order. Due to this ambiguity, comparing antidepressants and augmentation agents on the basis of their efficacy, tolerability, and speed of symptom relief would be beneficial for clinicians. To accomplish this, a systematic search was conducted following PRISMA guidelines. Only randomized controlled trials were included in this qualitative synthesis, resulting in 66 articles. This review identified several effective pharmaco-therapeutic strategies that are currently available for patients with TRD. Ketamine and esketamine appear to be effective for the treatment of TRD. Augmentation with certain second generation antipsychotics, such as quetiapine or aripiprazole is likewise effective, and may be preferred over switching to antidepressant monotherapy. While the combination of olanzapine and fluoxetine was one of the first pharmacotherapy approved for TRD, and its use may be limited by metabolic side-effects. Other effective strategies include augmentation with lithium, liothyronine (T3), lamotrigine, or combination of antidepressants including bupropion, tricyclics, or mirtazapine. There is insufficient research to demonstrate the efficacy of ziprasidone or levothyroxine (T4). A shared decision-making approach is recommended to guide treatment selection to address each patient's individual needs.

Authors+Show Affiliations

Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32512768

Citation

Ruberto, Valerie L., et al. "Pharmacological Treatments for Patients With Treatment-Resistant Depression." Pharmaceuticals (Basel, Switzerland), vol. 13, no. 6, 2020.
Ruberto VL, Jha MK, Murrough JW. Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel). 2020;13(6).
Ruberto, V. L., Jha, M. K., & Murrough, J. W. (2020). Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel, Switzerland), 13(6). https://doi.org/10.3390/ph13060116
Ruberto VL, Jha MK, Murrough JW. Pharmacological Treatments for Patients With Treatment-Resistant Depression. Pharmaceuticals (Basel). 2020 Jun 4;13(6) PubMed PMID: 32512768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological Treatments for Patients with Treatment-Resistant Depression. AU - Ruberto,Valerie L, AU - Jha,Manish K, AU - Murrough,James W, Y1 - 2020/06/04/ PY - 2020/04/29/received PY - 2020/05/25/revised PY - 2020/05/30/accepted PY - 2020/6/10/entrez KW - antidepressant KW - depression KW - ketamine KW - lithium KW - major depressive disorder KW - pharmacotherapy KW - treatment resistant JF - Pharmaceuticals (Basel, Switzerland) JO - Pharmaceuticals (Basel) VL - 13 IS - 6 N2 - Over a third of patients with major depressive disorder (MDD) do not have an adequate response to first-line antidepressant treatments, i.e., they have treatment-resistant depression (TRD). These patients tend to have a more severe course of illness and are at an increased risk of suicide. Next step treatment options for patients with TRD, include switching to a different antidepressant, combining more than one antidepressant, or augmenting an antidepressant with another (non-antidepressant) medication. It is unclear which of these treatment approaches should be applied to a given patient, and in what order. Due to this ambiguity, comparing antidepressants and augmentation agents on the basis of their efficacy, tolerability, and speed of symptom relief would be beneficial for clinicians. To accomplish this, a systematic search was conducted following PRISMA guidelines. Only randomized controlled trials were included in this qualitative synthesis, resulting in 66 articles. This review identified several effective pharmaco-therapeutic strategies that are currently available for patients with TRD. Ketamine and esketamine appear to be effective for the treatment of TRD. Augmentation with certain second generation antipsychotics, such as quetiapine or aripiprazole is likewise effective, and may be preferred over switching to antidepressant monotherapy. While the combination of olanzapine and fluoxetine was one of the first pharmacotherapy approved for TRD, and its use may be limited by metabolic side-effects. Other effective strategies include augmentation with lithium, liothyronine (T3), lamotrigine, or combination of antidepressants including bupropion, tricyclics, or mirtazapine. There is insufficient research to demonstrate the efficacy of ziprasidone or levothyroxine (T4). A shared decision-making approach is recommended to guide treatment selection to address each patient's individual needs. SN - 1424-8247 UR - https://www.unboundmedicine.com/medline/citation/32512768/Pharmacological_Treatments_for_Patients_with_Treatment-Resistant_Depression L2 - https://www.mdpi.com/resolver?pii=ph13060116 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.